Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 3/20 | 0.40 |
| ▸ | PDE6D | O43924 | 2/20 | 0.40 |
| ▸ | PDE6A | P16499 | 2/20 | 0.40 |
| ▸ | PDE6G | P18545 | 2/20 | 0.40 |
| ▸ | PDE6B | P35913 | 2/20 | 0.40 |
| ▸ | PDE6C | P51160 | 2/20 | 0.40 |
| ▸ | PDE6H | Q13956 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PDE9A | O76083 | 1/20 | 0.35 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1925922 | 0.99 | PDE5A (0.39) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL1926829 | 0.97 | PDE5A (0.39) | PDE5APDE6DPDE6APDE6GPDE6B | |
| Hydrochloric Acid SCHEMBL1926731 | 0.96 | PDE5A (0.38) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL1925108 | 0.89 | MEN1 (0.43) | KDM4EHSD17B10MEN1KMT2ASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL1925573 | 0.88 | MEN1 (0.43) | KDM4EHSD17B10MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL27535201 | 0.85 | SYK (0.36) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1924072 | 0.85 | SLC6A4 (0.36) | MEN1KMT2ATP53 | |
| SCHEMBL1925331 | 0.84 | KDM4E (0.38) | PDE5AKDM4EHSD17B10MEN1KMT2A | |
| SCHEMBL1924333 | 0.84 | NR1H2 (0.42) | — | |
| SCHEMBL1925575 | 0.84 | SCN9A (0.37) | SMN1; SMN2PDE9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1431293-B1 | WATER-SOLUBLE PHENYLPYRIDAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME | KOWA CO (JP) | 2011-06-08 | — | — | EP | disclosed |
| US-7211577-B2 | Water-soluble phenylpyridazine derivative and medicine containing the same | KOWA CO., LTD. (JP) | 2007-05-01 | — | — | US | disclosed |
| CN-1304379-C | Water-soluble phenylpyridazine compounds and compositions containing the same | KOWA CO (JP) | 2007-03-14 | — | — | CN | disclosed |
| US-7087606-B2 | Water-soluble phenylpyridazine compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2006-08-08 | — | — | US | disclosed |
| US-20060142292-A1 | 4-(4-tert-butoxycarbonyl-1-piperazinyl)methyl-6-(3-fluoro-4-methylphenyl)-2-isobutyl-2H-pyridazin-3-one;inhibiting interleukin-1 beta, high water solubility and oral absorbability; treating immune system diseases, inflammatory diseases, and ischemic diseases | KOWA CO., LTD. (JP) | 2006-06-29 | — | — | US | disclosed |
| CN-1759103-A | Water-soluble phenylpyridazine derivative and medicine containing the same | KOWA CO (JP) | 2006-04-12 | — | — | CN | disclosed |
| EP-1604984-A1 | WATER-SOLUBLE PHENYLPYRIDAZINE DERIVATIVE AND MEDICINE CONTAINING THE SAME | Kowa Co., Ltd. (JP) | 2005-12-14 | — | — | EP | disclosed |
| US-20050085480-A1 | Water-soluble phenylpyridazine compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| US-6869954-B2 | Water-soluble phenylpyridazine compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2005-03-22 | — | — | US | disclosed |
| US-6861428-B2 | Water-soluble phenylpyridazine compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2005-03-01 | — | — | US | disclosed |
| CN-1558903-A | Water-soluble phenylpyridazine derivative and drug containing the same | ������������ʽ���� | 2004-12-29 | — | — | CN | disclosed |
| EP-1431293-A1 | WATER-SOLUBLE PHENYLPYRIDAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME | Kowa Co., Ltd. (JP) | 2004-06-23 | — | — | EP | disclosed |
| US-20040002497-A1 | Water-soluble phenylpyridazine compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2004-01-01 | — | — | US | disclosed |
| US-20030119838-A1 | Water-soluble phenylpyridazine compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2003-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142292-A1 | 4-(4-tert-butoxycarbonyl-1-piperazinyl)methyl-6-(3-fluoro-4-methylphenyl)-2-isobutyl-2H-pyridazin-3-one;inhibiting interleukin-1 beta, high water solubility and oral absorbability; treating immune system diseases, inflammatory diseases, and ischemic diseases | IL1B, IL1A, IL1R1 | PDE5A 1382/4885PDE6D 4188/4885PDE6A 4646/4885 |
| US-20030119838-A1 | Water-soluble phenylpyridazine compounds and compositions containing the same | IL1A, IL1B, IL1R1 | PDE5A 853/4885PDE6D 2916/4885PDE6A 4509/4885 |
| US-20040002497-A1 | Water-soluble phenylpyridazine compounds and compositions containing the same | IL1A, IL1B, IL1R1 | PDE5A 756/4885PDE6D 2555/4885PDE6A 4394/4885 |
| US-20050085480-A1 | Water-soluble phenylpyridazine compounds and compositions containing the same | IL1A, IL1B, IL1R1 | PDE5A 537/4885PDE6D 2652/4885PDE6A 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.